表紙
市場調查報告書

內質素:開發平台分析

Endoplasmin - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 920813
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
內質素:開發平台分析 Endoplasmin - Pipeline Review, H1 2020
出版日期: 2020年02月28日內容資訊: 英文 52 Pages
簡介

本報告提供內質素的開發情形調查分析,開發中產品的概要,臨床實驗的各階段的產品概要,主要企業簡介,藥物的簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

內質素概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各適應症
  • 企業開發中的產品
  • 在大學、研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Agenus Inc
  • Amgen Inc
  • Heat Biologics Inc

藥物簡介

產品開發里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2266TDB

Summary

Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Heat shock protein 90kDa beta member 1 (HSP90B1), known also as endoplasmin. It functions in the processing and transport of secreted proteins and endoplasmic reticulum associated degradation (ERAD).

Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Discovery stages are 2, 1 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology which include indications Glioblastoma Multiforme (GBM), Gliosarcoma, Non-Small Cell Lung Cancer, Recurrent Glioblastoma Multiforme (GBM) and Solid Tumor.

The latest report Endoplasmin - Pipeline Review, H1 2020, outlays comprehensive information on the Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1)
  • The report reviews Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Overview
  • Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Companies Involved in Therapeutics Development
    • Agenus Inc
    • Amgen Inc
    • Heat Biologics Inc
  • Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Drug Profiles
    • G-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • G-200 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HS-130 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Panvotinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit GRP94 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vitespen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Dormant Products
  • Endoplasmin (94 kDa Glucose Regulated Protein or Heat Shock Protein 90 kDa Beta Member 1 or Tumor Rejection Antigen 1 or gp96 Homolog or HSP90B1) - Product Development Milestones
    • Featured News & Press Releases
      • Dec 16, 2019: Heat Biologics announces first patient dosed in the first phase 1 trial of HS-130
      • Aug 12, 2019: Heat Biologics announces FDA clearance of IND application to begin phase 1 trial of HS-130 in combination with Heat's HS-110
      • Apr 02, 2019: Heat Biologics delivers poster presentation at the AACR Annual Meeting 2019
      • Jun 01, 2015: Updated Phase 2 Data of Prophage In Newly Diagnosed GBM Presented at ASCO
      • May 14, 2015: Agenus Announces Oral Presentation at ASCO Highlighting Improved Survival with Prophage Immunotherapy in Brain Cancer Compared to Historical Controls
      • Jul 01, 2014: Agenus Brain Cancer Vaccine Shows Extended Survival in Phase 2 Final Data Analysis
      • Jan 21, 2014: Agenus' Prophage Vaccine for Glioma Hailed As a 'Very Promising Therapy' in an Editorial Published in the Journal Neuro-Oncology
      • Dec 16, 2013: Positive Phase 2 Results from Agenus' Brain Cancer Vaccine Published in Neuro-Oncology
      • Sep 17, 2013: Agenus Reports Positive Follow-on Phase 2 Results for Brain Cancer Vaccine in Newly Diagnosed Patients
      • May 22, 2013: Agenus Announces Initiation Of Enrollment In NCI-sponsored Randomized Trial Of Prophage G-200 Vaccine With Avastin In Treatment Of Brain Tumors
      • May 01, 2013: Agenus Announces Presentation Of Preliminary Data From Phase II Clinical Trial Of Brain Cancer Vaccine At AANS Meeting
      • Apr 10, 2013: Agenus Presents Brain Cancer Vaccine Results At 81st AANS Annual Scientific Meeting 2013
      • Aug 08, 2012: Agenus Announces Publication Of Key Data Showing Antitumor Activity Of Prophage Vaccine In Clinical Cancer Research
      • Apr 17, 2012: Agenus Presents New Phase II Data From Brain Cancer Study Of Prophage Vaccine At Plenary Session Of AANS
      • Apr 17, 2012: NCI Group Selects HSPPC-96 Vaccine For Randomized Large-Scale Study With Bevacizumab For Recurrent Glioblastoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Agenus Inc, H1 2020
  • Pipeline by Amgen Inc, H1 2020
  • Pipeline by Heat Biologics Inc, H1 2020
  • Dormant Projects, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020